To investigate potential combination regimens containing DMD and OPC-167832 (DC) as a core component (i.e., DC-based regimens), we evaluated the therapeutic effects of DC as part of 3- or 4-drug combination regimens in TB-infected mice and compared them to that of the standard regimen, RHZE (RIF, INH, PZA, and EMB). Here, DMD is linked to tuberculosis.